Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Phase 3 KEYNOTE-789 Study - Pemetrexed & Platinum +/- Pembro for TKI-Resistant, EGFRm, Metastatic Non-Squamous NSCLC"

249 views
June 15, 2023
Comments 0
Login to view comments. Click here to Login